Spermatogenesis is the creation of mature sperm from germ cells. Early-stage germ cells, called spermatagonia, reside in the periphery of seminiferous tubules of the testis. This population contains both stem cells and differentiating spermatogonia, which undergo a series of mitotic divisions to amplify the number of cells. Germ cells then enter meiosis, the second phase of spermatogenesis, and are called spermatocytes. During meiosis, genetic recombination occurs and spermatocytes undergo two divisions which halves the number of chromosomes present in each cell.
During spermiogenesis, the final phase of spermatogenesis, haploid germ cells (spermatids) undergo extensive changes and become more like what we think of as traditional sperm, with tails and other structures like the acrosome.
Finally, the non-motile spermatozoa are transported to the epididymis. Sperm undergo a maturation process as they transit the epididymis. As a result, they acquire the capacity for forward motility and become capable of fertilization.
One way to influence spermatogenesis is through the manipulation of hormone levels. There are ongoing clinical trials focused on creating hormonal male contraceptives, but there are multiple non-hormonal approaches to stop spermatogenesis or interfere with epididymal maturation.
A drug that stops spermatogenesis would have interesting characteristics, including a potential onset time of 2-3 months . This is because it takes quite some time for sperm to develop and get ready for action, and even after ceasing spermatogenesis, all of the existing sperm in the pipeline would still remain.
MCI has funded projects in this space, such as Gunda Georg at University of Minnesota and her work on TSSK1/2. Other projects at institutions worldwide are focused on diverse approaches to temporarily disrupt spermatogenesis or epididymal maturation so that functional sperm are not produced.
Xu, B., Hao, Z., Jha, K. N., Zhang, Z., Urekar, C., Digilio, L., … & Herr, J. C. (2008). Targeted deletion of Tssk1 and 2 causes male infertility due to haploinsufficiency. Developmental biology, 319(2), 211-222.
Griswold, M. D. (2016). Spermatogenesis: The Commitment to Meiosis. Physiological Reviews, 96(1), 1–17. https://doi.org/10.1152/physrev.00013.2015
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., … & Knapp, S. (2012). Small-molecule inhibition of BRDT for male contraception. Cell, 150(4), 673-684.
Chung, S. S., Wang, X., Roberts, S. S., Griffey, S. M., Reczek, P. R., & Wolgemuth, D. J. (2011). Oral administration of a retinoic acid receptor antagonist reversibly inhibits spermatogenesis in mice. Endocrinology, 152(6), 2492-2502.
Ayoub, R., Page, S. T., Swerdloff, R. S., Liu, P. Y., Amory, J. K., Leung, A., … Wang, C. (2016). Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive. Andrology, 5(2), 278–285. https://doi.org/10.1111/andr.12303
Zitzmann, M., Rohayem, J., Raidt, J., Kliesch, S., Kumar, N., Sitruk-Ware, R., & Nieschlag, E. (2017). Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial. Andrology, 5(3), 516–526. https://doi.org/10.1111/andr.12328